Adrixetinib (Q702)

Adrixetinib · Qurient Co., Ltd

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Adrixetinib (Q702), covering 2025-12-30 to 2025-12-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease [Phase 1]